Kymera Therapeutics (KYMR) Other Operating Expenses (2023 - 2026)

Kymera Therapeutics (KYMR) has 4 years of Other Operating Expenses data on file, last reported at $73.2 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 35.87% year-over-year to $73.2 million in Q1 2026; TTM through Mar 2026 was $30.2 million, a 79.3% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 97.59% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $73.2 million, up from -$161.1 million in the prior quarter.
• Over the last five years, Other Operating Expenses for KYMR reached as high as $94.4 million in Q4 2023 and fell as low as -$161.1 million in Q4 2025.
• Historically, Other Operating Expenses has averaged $30.6 million across 4 years, with a median of $53.9 million in 2025.
• On a YoY basis, Other Operating Expenses climbed as much as 993.95% in 2025 and fell as far as 456.32% in 2025.
• Year by year, Other Operating Expenses stood at $94.4 million in 2023, then tumbled by 52.1% to $45.2 million in 2024, then sank by 456.32% to -$161.1 million in 2025, then surged by 145.44% to $73.2 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $73.2 million in Q1 2026, -$161.1 million in Q4 2025, and $56.0 million in Q3 2025.